ORIC Pharmaceuticals
Update in progressORIC (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
ORIC Pharmaceuticals is a clinical-stage biopharma focused on therapies to overcome cancer resistance mechanisms. Its candidates include enozertinib (ORIC-114), a brain-penetrant, orally bioavailable irreversible EGFR inhibitor targeting EGFR exon 20 and exon 20 insertions, in Phase 1b; and rinzimetostat (ORIC-944), an allosteric EZH2/PRC2 inhibitor for prostate cancer in Phase 1b. It has collaboration agreements with Bayer and Johnson & Johnson. Founded in 2014, based in South San Francisco.
Company score
- Sentiment
- 0.14
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.07
- Governance
- 0.03
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.06
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Jacob M. Chacko M.B.A., M.D.
- Founded2014
- Employees111
- Websitewww.oricpharma.com
Identifiers
- ISINUS68622P1093
- FIGIBBG00BL5SLH5
- LEI54930033FJRNEYBW0L25
- CUSIP68622P109
- CIK0001796280